Přednášky a postery
Vybrané prezentace a postery (pouze s mezinárodní účastí):
Vachtenheim J, Réda J, Vlčková K, Ondrušová L: Treatment of human melanoma cells with dasatinib requires inactivation of both mTOR and MAPK pathways to achieve high cell eradication efficacy. American Association for Cancer Research (AACR) Annual Meeting, 29. March - 3. April 2019, Atlanta, GA, USA. Poster.
Vlčková K, Réda J, Vachtenheim J, Horák P, Ondrušová L: Exprese hlavních komponent signální dráhy Hedgehog v lidských nádorových liniích a inhibice nádorových buněk pomocí inhibitoru GLI faktorů GANT61, PragueOnco 2019, 10. pražské mezioborové onkologické kolokvium, 23. – 25. leden 2019, Praha, Česká republika. Poster.
Vlčková K, Vachtenheim J, Réda J, Horák P, Ondrušová L: Iinducibilní snížení hladiny MITF snižuje diferenciaci melanomových buněk, ale neovlivňuje proliferaci ani “phenotype switching”. PragueOnco 2018, 9. pražské mezioborové onkologické kolokvium, 24. - 26. 1eden 2018, Praha, Česká republika. Poster.
Vachtenheim J, Vlčková K, Réda J, Ondrušová L: Survivin is a Novel Target of the Hedgehog/GLI2 Signaling Pathway in Human Cancer Cells. WGC BIT´s 9th World Gene Convention – 2018, Singapore, 13. - 15. November 2018. J. Vachtenheim-invited speaker.
Vlčková K, Vachtenheim J, Réda J, Horák P, Ondrušová L: Inducibly decreased MITF levels do not markedly change proliferation and invasion but reduce differentiation of melanoma cells. The 43rd FEBS Congress, 7. - 12. July 2018, Prague, Czech Republic. Poster.
Vachtenheim J, Vlčková K, and Réda J: The decrease of MITF, a crucial melanoma transcription factor, does not induce marks of epithelial- mesenchymal transition, maintains the proliferation and invasivity, but diminish the differentiation of melanoma cells. 16th Global Annual Oncologists Meeting. 24. - 25. April, 2017, Dubai, UAE. J. Vachtenheim-invited speaker.
Vachtenheim J: GLI2, a Hedgehog Signaling Pathway Effector, is a Transcription Activator of Survivin Expression in Human Tumor Cells. 12th World Cancer Conference. 26. - 28. September, 2016, London, UK. J. Vachtenheim-invited speaker.
Vlčková K, Vachtenheim J, Ondrušová L, Réda J, Dundr P, Zadinová M: Survivin as a novel target of the Hedgehog signaling pathway effector Gli2 in human cancer. 21th World Congress on Advances in Oncology & 19th International Symposium on Molecular Medicine. 6. - 8. October, 2016, Athens, Greece. J. Vachtenheim-invited speaker.
Vachtenheim, J. Réda, L. Ondrušová, K. Vlčková K: Treatment with GANT61 and obatoclax as an effective combination of melanoma therapy irrespective of braf mutational status in a preclinical study. Abstract. 19th European Society for Pigment Cell Research Meeting, Edinburgh, 15. - 18. September 2015. Pigment Cell Melanoma Res., 28, 2015, p. 17-18. Poster.
Vlčková K, Ondrušová L, Réda J, Vachtenheim J, Žáková P: Survivin is a novel target of the Hedgehog/GLI signaling pathway in human tumor cell lines. 106th American Association for Cancer Research (AACR) Annual Meeting. 18. - 22. April, 2015. Philadelphia, PA, USA. Poster.
Vlčková K, Ondrušová L, Vachtenheim J, Réda J, Dundr P, Zadinová M, Žáková P, Poučková P: Survivin is a novel target of the Hedgehog/GLI signaling pathway in human tumor cell lines. 15th Central European Lung Cancer Conference. 28. - 30. November, 2015. Prague, Czech Republic. J. Vachtenheim-invited speaker.
Vachtenheim J, Réda J, Ondrušová L, Žáková P: The requirements for dasatinib sensitivity in human melanoma cell lines. American Association for Cancer Research (AACR) Annual Meeting, 5. - 9. April 2014, San Diego, CA, USA. Poster.
Ondrušová L, Vachtenheim J, Réda J: SWI/SNF complex activates the expression of survival genes in melanoma. Melanocytes and melanoma: from basic science to clinical applications. 18.-20. June, 2012, Malmő, Sweden. Poster.
